Nutrição e Osteoporose – Artigo 14
Parathyroid Hormone and Parathyroid Hormone-related Protein Analogs in Osteoporosis Therapy
Abstract
Purpose—To review the efficacy and optimal use of parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis treatment.
Recent findings—The parathyroid hormone analog teriparatide, a potent stimulator of bone remodeling, increases hip and spine bone mineral density and reduces the risk of vertebral and non-vertebral fractures in postmenopausal osteoporotic women. The parathyroid hormone-related protein analog, abaloparatide, also reduces fracture incide...
Nutrição e Osteoporose – Artigo 13
Oxidative Stress-Related Biomarkers in Postmenopausal Osteoporosis: A Systematic Review and Meta-Analyses
Numerous studies suggested that oxidative stress (OS) played a central role in the onset and development of postmenopausal osteoporosis (PO); however, conflicting results were obtained as to the association of OS-related biomarkers and PO. This metaanalysis aimed to identify the association between these markers and PO, and explore factors that may explain the inconsistencies in these results. A systematic literature search was conducted in relevant database. Search terms and ...
Nutrição e Osteoporose – Artigo 12
Osteoporosis and Sarcopenia in Older Age
Abstract
Osteoporosis and sarcopenia are common in older age and associated with significant morbidity and mortality. Consequently, they are both attended by a considerable socioeconomic burden. Osteoporosis was defined by the World Health Organisation (WHO) in 1994 as a bone mineral density of less than 2.5 standard deviations below the sex-specific young adult mean and this characterisation has been adopted globally. Subsequently, a further step forward was taken when bone mineral density was incorporated into fracture risk prediction ...
Nutrição e Osteoporose – Artigo 11
Osteoporosis and fracture risk in older people
Introduction
Until the 1940s, when Albright associated osteoporosis with a defect of bone anabolism, it was not considered a disease entity but an inevitable consequence of the ageing process for which there was little remedy.1 Bisphosphonates, first synthesised in the 1800s but in clinical use only since the 1960s, demonstrated that this process of age-related decline in bone was, in fact, modifi able.2 More recently, a wealth of basic and clinical research has greatly enhanced our understanding of the complexity of bone metabolism, ...
Nutrição e Osteoporose – Artigo 10
Nutrition and osteoporosis prevention for the orthopaedic surgeon: a wholefoods approach
Introduction
Osteoporosis is a silent but progressive disease affecting the density and quality of bone while greatly increasing
fracture risk.1 Globally, around one in three women and one in five men are at risk of an osteoporotic fracture, with the most common fractures being at the hip, spine or wrist.1 The pathogenesis of osteoporosis is multi-faceted, consisting of intricate interplay between physiological processes, including hormonal status, along with genetic and environmental ...
Nutrição e Osteoporose – Artigo 9
Managing Osteoporosis Patients after Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Abstract
Bisphosphonates (BPs) are the most commonly used medications for osteoporosis, but optimal duration of therapy is unknown. This ASBMR report provides guidance on BP therapy duration with a risk benefit perspective.
Two trials provided evidence for long-term BP use. In the Fracture Intervention Trial Long-term Extension (FLEX), postmenopausal women receiving alendronate for 10 years had fewer clinical vertebral fractures than ...
Nutrição e Osteoporose – Artigo 8
Management of Osteoporosis in Chronic Kidney Disease
Abstract:
Chronic kidney disease (CKD) patients with coexisting osteoporosis are becoming common. Many of the therapeutic agents used to treat osteoporosis are known to be affected by the renal function. It is generally
thought that osteoporosis in G1 to G3 CKD patients can be treated as in non-CKD patients with osteoporosis. In stage 4 or more advanced CKD patients and CKD patients on dialysis with osteoporosis, however, bisphosphonates must be used with caution, bearing in mind the potential development of such disorders as ady...
Nutrição e Osteoporose – Artigo 7
International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates
Abstract
Background—Low adherence to oral bisphosphonates is a common problem that jeopardizes the efficacy of treatment of osteoporosis. No clear screening strategy for the assessment of compliance is widely accepted in these patients.
Methods—The International Osteoporosis Foundation and the European Calcified Tissue Society have convened a working group to propose a screening strategy to detect a lack of adherence ...
